Article
Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer.
British journal of cancer - 1 Apr 2020
van Geel Robin M J M, van Brummelen Emilie M J, Eskens Ferry A L M, Huijberts Sanne C F A, de Vos Filip Y F L, Lolkema Martijn P J K, Devriese Lot A, Opdam Frans L, Marchetti Serena, Steeghs Neeltje, Monkhorst Kim, Thijssen Bas, Rosing Hilde, Huitema Alwin D R, Beijnen Jos H, Bernards René, Schellens Jan H M
Abstract excerpt
BACKGROUND: Mutations in KRAS result in a constitutively activated MAPK pathway. In KRAS-mutant tumours existing treatment options, e.g. MEK inhibition, have limited efficacy due to resistance through feedback activation of epidermal growth factor receptors (HER). METHODS: In this Phase 1 study, the pan-HER inhibitor dacomitinib was combined with the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutant...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.